247 related articles for article (PubMed ID: 15490060)
1. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
Sywak MS; Pasieka JL; McEwan A; Kline G; Rorstad O
World J Surg; 2004 Nov; 28(11):1157-62. PubMed ID: 15490060
[TBL] [Abstract][Full Text] [Related]
2. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
3. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases.
Prvulovich EM; Stein RC; Bomanji JB; Ledermann JA; Taylor I; Ell PJ
J Nucl Med; 1998 Oct; 39(10):1743-5. PubMed ID: 9776280
[TBL] [Abstract][Full Text] [Related]
4. [Contribution of 131I MIBG scintigraphy in the diagnosis of carcinoid tumors of the digestive tract. Experience of 14 cases].
Siproudhis L; Lescouarc'h J; Bretagne JF; Bourguet P; Raoul JL; Etienne PL; Herry JY; Gosselin M
Gastroenterol Clin Biol; 1991; 15(11):789-93. PubMed ID: 1769467
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
[TBL] [Abstract][Full Text] [Related]
7. Results of [131I]metaiodobenzylguanidine treatment in metastatic carcinoid.
Bestagno M; Pizzocaro C; Pagliaini R; Rossini PL; Guerra P
J Nucl Biol Med (1991); 1991; 35(4):343-5. PubMed ID: 1823854
[TBL] [Abstract][Full Text] [Related]
8. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results of [131I]metaiodobenzylguanidine treatment in metastatic carcinoid tumors.
Colombo L; Vignati A; Lomuscio G; Dottorini ME
J Nucl Biol Med (1991); 1991; 35(4):352-4. PubMed ID: 1823856
[TBL] [Abstract][Full Text] [Related]
10. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Taal BG; Hoefnagel CA; Valdes Olmos RA; Boot H; Beijnen JH
J Clin Oncol; 1996 Jun; 14(6):1829-38. PubMed ID: 8656251
[TBL] [Abstract][Full Text] [Related]
11. [Radiation therapy with 131I-MIBG is still relevant for metastatic carcinoid tumors].
Oudoux A; Bridji B; Resche I; Ricaud M; Douillard JY; Chatal JF; Rousseau C
Gastroenterol Clin Biol; 2005; 29(8-9):935-8. PubMed ID: 16294166
[TBL] [Abstract][Full Text] [Related]
12. Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report.
Dworakowska D; Gueorguiev M; Laji K; Grossman AB
Endokrynol Pol; 2008; 59(4):342-7. PubMed ID: 18777505
[TBL] [Abstract][Full Text] [Related]
13. Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours.
Zuetenhorst JM; Valdes Olmos RA; Muller M; Hoefnagel CA; Taal BG
Endocr Relat Cancer; 2004 Sep; 11(3):553-61. PubMed ID: 15369454
[TBL] [Abstract][Full Text] [Related]
14. Role of [131I]metaiodobenzylguanidine therapy in carcinoids.
Hoefnagel CA; Taal BG; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):346-8. PubMed ID: 1726678
[TBL] [Abstract][Full Text] [Related]
15. Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination.
Zuetenhorst H; Taal BG; Boot H; Valdes Olmos R; Hoefnagel C
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1157-64. PubMed ID: 10524647
[TBL] [Abstract][Full Text] [Related]
16. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
17. [131I]metaiodobenzylguanidine therapy in carcinoid tumors.
Castellani MR; Di Bartolomeo M; Maffioli L; Zilembo N; Gasparini M; Buraggi GL
J Nucl Biol Med (1991); 1991; 35(4):349-51. PubMed ID: 1823855
[TBL] [Abstract][Full Text] [Related]
18. Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Jul; 40(7):564-6. PubMed ID: 25546192
[TBL] [Abstract][Full Text] [Related]
19. Midgut carcinoid tumours: surgical treatment and prognosis.
Kerström G; Hellman P; Hessman O
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):717-28. PubMed ID: 16253896
[TBL] [Abstract][Full Text] [Related]
20. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome.
Pathirana AA; Vinjamuri S; Byrne C; Ghaneh P; Vora J; Poston GJ
Eur J Surg Oncol; 2001 Jun; 27(4):404-8. PubMed ID: 11417988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
